Search research articles
Contact Us
Filters
Showing results (101-110 of 178) with videos related to
Page
of 18
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
November 15, 2022
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101
Emilie Le Rhun, Felix Boakye Oppong, Martin van den Bent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2006
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial
René-Olivier Mirimanoff, Thierry Gorlia, Warren Mason, et al.
World Journal of Gastroenterology
|
June 17, 2021
Molecular alterations in pancreatic tumors
Michela Visani, Giorgia Acquaviva, Antonio De Leo, et al.
Critical Reviews in Oncology/Hematology
|
January 21, 2015
New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology
Alba A Brandes, Marco Bartolotti, Gianluca Marucci, et al.
Journal of Neuro-Oncology
|
November 5, 2014
Post progression survival in glioblastoma: where are we?
Enrico Franceschi, Mario Ermani, Stefania Bartolini, et al.
Neuro-Oncology Practice
|
March 20, 2025
Health-related quality of life in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only: Secondary outcome of the randomized phase III EORTC 26101 study
Linda Dirven, Abigirl Machingura, Martin J van den Bent, et al.
The Oncologist
|
February 20, 2019
Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?
Enrico Franceschi, Alicia Tosoni, Dario De Biase, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 31, 2013
New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951
Thierry Gorlia, Jean-Yves Delattre, Alba A Brandes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2008
Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
Eric Raymond, Alba A Brandes, Christian Dittrich, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 13, 2021
Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial)
Giuseppe Lombardi, Paola Del Bianco, Alba A Brandes, et al.
Page
of 18
Search research articles
Search
Showing results (101-110 of 178) with videos related to
Sort By:
Page
of 18
European Journal of Cancer (Oxford, England : 1990)
|
November 15, 2022
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101
Emilie Le Rhun, Felix Boakye Oppong, Martin van den Bent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2006
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial
René-Olivier Mirimanoff, Thierry Gorlia, Warren Mason, et al.
World Journal of Gastroenterology
|
June 17, 2021
Molecular alterations in pancreatic tumors
Michela Visani, Giorgia Acquaviva, Antonio De Leo, et al.
Critical Reviews in Oncology/Hematology
|
January 21, 2015
New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology
Alba A Brandes, Marco Bartolotti, Gianluca Marucci, et al.
Journal of Neuro-Oncology
|
November 5, 2014
Post progression survival in glioblastoma: where are we?
Enrico Franceschi, Mario Ermani, Stefania Bartolini, et al.
Neuro-Oncology Practice
|
March 20, 2025
Health-related quality of life in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only: Secondary outcome of the randomized phase III EORTC 26101 study
Linda Dirven, Abigirl Machingura, Martin J van den Bent, et al.
The Oncologist
|
February 20, 2019
Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?
Enrico Franceschi, Alicia Tosoni, Dario De Biase, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 31, 2013
New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951
Thierry Gorlia, Jean-Yves Delattre, Alba A Brandes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2008
Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
Eric Raymond, Alba A Brandes, Christian Dittrich, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 13, 2021
Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial)
Giuseppe Lombardi, Paola Del Bianco, Alba A Brandes, et al.
Page
of 18